Gene: FCGR2A

2212
CD32|CD32A|CDw32|FCG2|FCGR2|FCGR2A1|FcGR|IGFR2
Fc fragment of IgG receptor IIa
protein-coding
1q23.3
Ensembl:ENSG00000143226 MIM:146790 Vega:OTTHUMG00000034469 UniprotKB:P12318
NG_012066.2
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.920e-1 (AD)  6.373e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TLR20.951
FPR10.95
PTPRC0.944
HCK0.942
LAIR10.938
FCGR3A0.936
CD300A0.934
FCER1G0.934
HCLS10.933
FCGR1A0.931

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KCNIP3-0.54
MARCH4-0.527
NEUROD6-0.512
ZSCAN1-0.497
TMEM179-0.493
WNT7A-0.49
ABCC12-0.489
CPLX3-0.487
DLK2-0.484
ST6GAL2-0.482

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00002CetuximabBiotechDrug205923-56-4ApprovedTarget
DB00005EtanerceptBiotechDrug185243-69-0Approved|InvestigationalTarget
DB00028Immune Globulin HumanBiotechDrug9007-83-4Approved|InvestigationalTarget
DB00051AdalimumabBiotechDrug331731-18-1ApprovedTarget
DB00054AbciximabBiotechDrug143653-53-6ApprovedTarget
DB00056Gemtuzumab ozogamicinBiotechDrug220578-59-6Approved|InvestigationalTarget
DB00072TrastuzumabBiotechDrug180288-69-1Approved|InvestigationalTarget
DB00073RituximabBiotechDrug174722-31-7ApprovedTarget
DB00074BasiliximabBiotechDrug179045-86-4Approved|InvestigationalTarget
DB00075MuromonabBiotechDrug140608-64-6Approved|InvestigationalTarget
DB00078Ibritumomab tiuxetanBiotechDrug206181-63-7Approved|InvestigationalTarget
DB00081TositumomabBiotechDrug208921-02-2Approved|InvestigationalTarget
DB00087AlemtuzumabBiotechDrug216503-57-0Approved|InvestigationalTarget
DB00092AlefaceptBiotechDrug222535-22-0Approved|Investigational|WithdrawnTarget
DB00095EfalizumabBiotechDrug214745-43-4Approved|InvestigationalTarget
DB00108NatalizumabBiotechDrug189261-10-7Approved|InvestigationalTarget
DB00110PalivizumabBiotechDrug188039-54-5Approved|InvestigationalTarget
DB00111DaclizumabBiotechDrug152923-56-3Investigational|WithdrawnTarget
DB00112BevacizumabBiotechDrug216974-75-3Approved|InvestigationalTarget
DB06607CatumaxomabBiotechDrug509077-98-9Approved|Investigational|WithdrawnTarget
DB11767SarilumabBiotechDrug1189541-98-7Approved|InvestigationalTarget
ID Drug Name Action PubMed
D000395Air Pollutants, Occupational"Air Pollutants, Occupational results in decreased expression of FCGR2A mRNA"23195993
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in decreased expression of FCGR2A mRNA28522335
D000643Ammonium ChlorideAmmonium Chloride affects the expression of FCGR2A mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of FCGR2A mRNA24449571
C006780bisphenol A[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of FCGR2A promoter23359474
C006780bisphenol Abisphenol A results in increased expression of FCGR2A mRNA25181051
D002065BuspironeBuspirone results in decreased expression of FCGR2A mRNA24136188
D002509CephaloridineCephaloridine results in increased expression of FCGR2A mRNA18500788
C009160cyclonitecyclonite results in increased expression of FCGR2A mRNA25559034
D016572CyclosporineCyclosporine results in increased expression of FCGR2A mRNA21865292
D003561CytarabineCytarabine results in increased expression of FCGR2A mRNA19194470
D003993Dibutyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of FCGR2A promoter23359474
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of FCGR2A mRNA21266533
D002945CisplatinCisplatin results in increased expression of FCGR2A mRNA27594783
D004051Diethylhexyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of FCGR2A promoter23359474
D002117CalcitriolCalcitriol results in decreased expression of FCGR2A mRNA26485663
D004237DiuronDiuron results in decreased expression of FCGR2A mRNA25152437
C082360fipronilfipronil results in increased expression of FCGR2A mRNA23962444
D005485FlutamideFlutamide results in decreased expression of FCGR2A mRNA24136188
D006493Heparin[Heparin binds to PF4 protein] which binds to FCGR2A protein8282825
D008727MethotrexateMethotrexate results in increased expression of FCGR2A mRNA17400583
C051752nefazodonenefazodone results in decreased expression of FCGR2A mRNA24136188
D009532NickelNickel results in decreased expression of FCGR2A mRNA23195993
D009532NickelNickel results in increased expression of FCGR2A mRNA24768652|2558310
C028007nickel monoxidenickel monoxide results in increased expression of FCGR2A mRNA19167457
C012655nimesulidenimesulide results in decreased expression of FCGR2A mRNA24136188
D010098OxycodoneOxycodone results in decreased expression of FCGR2A mRNA23439660
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of FCGR2A mRNA19162173
C006253pirinixic acidpirinixic acid results in decreased expression of FCGR2A mRNA19162173
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in decreased expression of FCGR2A mRNA19162173
D011441PropylthiouracilPropylthiouracil results in increased expression of FCGR2A mRNA24780913
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of FCGR2A mRNA23806026|2589566
C004648testosterone enanthatetestosterone enanthate affects the expression of FCGR2A mRNA17440010
D014050TolueneToluene results in decreased expression of FCGR2A mRNA22166486
D014241TrichloroethyleneTrichloroethylene results in increased methylation of FCGR2A gene27618143
C057693troglitazonetroglitazone results in increased expression of FCGR2A mRNA28973697
C025643vinclozolinvinclozolin results in increased expression of FCGR2A mRNA22570695

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25416956  
GO:0019864IgG binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0038096Fc-gamma receptor signaling pathway involved in phagocytosis-TAS-  
GO:0043312neutrophil degranulation-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
GO:0030667secretory granule membrane-TAS-  
KEGG ID KEGG Term
hsa04145Phagosome
hsa04380Osteoclast differentiation
hsa04666Fc gamma R-mediated phagocytosis
hsa05140Leishmaniasis
hsa05150Staphylococcus aureus infection
hsa05322Systemic lupus erythematosus
Reactome ID Reactome Term Evidence
R-HSA-168249Innate Immune SystemTAS
R-HSA-168249Innate Immune SystemIEA
R-HSA-168256Immune SystemTAS
R-HSA-168256Immune SystemIEA
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisTAS
R-HSA-2029480Fcgamma receptor (FCGR) dependent phagocytosisIEA
R-HSA-2029481FCGR activationIEA
R-HSA-2029481FCGR activationTAS
R-HSA-2029482Regulation of actin dynamics for phagocytic cup formationTAS
R-HSA-2029485Role of phospholipids in phagocytosisTAS
R-HSA-6798695Neutrophil degranulationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29744169Inflammatory mediator polymorphisms associate with initial periodontitis in adolescents. (2016 Dec)Heikkinen AMClin Exp Dent Res